
Alnylam-discovered cemdisiran, an siRNA silencing complement C5, is the first RNAi therapy approved for AChR-positive generalized myasthenia gravis.
This note demonstrates identification of Infliximab charge variants from intact mass analysis enabled by two-dimensional liquid chromatography







